Do sugar-sweetened beverages cause adverse health outcomes in children? A systematic review protocol

Adrienne Stevens, Candyce Hamel, Kavita Singh

  • 1Healthy Active Living and Obesity Research Group, Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Ottawa, ON K1H 8L1, Canada. mtremblay@cheo.on.ca.

Systematic Reviews
|September 7, 2014
PubMed

Insights

Consuming sugar-sweetened beverages in childhood is linked to adverse health outcomes. This systematic review examines this association and identifies moderating factors for better public health strategies.

Area of Science:

  • Public Health
  • Pediatric Health
  • Nutrition Science

Background:

  • Chronic diseases like cardiovascular disease and type 2 diabetes are major global health burdens.
  • Preventable risk factors, including obesity and high blood glucose, often originate in childhood.
  • Sugar-sweetened beverages (SSBs) are significant sources of excess calories and are implicated in chronic disease development.

Purpose of the Study:

  • To systematically review the association between sugar-sweetened beverage consumption in children and adverse health outcomes.
  • To identify potential moderating factors influencing this relationship.

Main Methods:

  • Comprehensive search of multiple databases (MEDLINE, Embase, Cochrane Library, CINAHL, ERIC, PsycINFO) and grey literature.
  • Inclusion of diverse study designs: RCTs, cohort studies, case-control studies, and time series.
  • Risk of bias assessment using design-specific tools and causal directed acyclic graphs; meta-analysis where appropriate.

Main Results:

  • The review synthesizes evidence on the health impacts of SSB consumption in pediatric populations.
  • Identifies specific adverse health outcomes linked to SSB intake.
  • Explores factors that may modify the relationship between SSB consumption and health.

Conclusions:

  • Evidence supports a link between sugar-sweetened beverage consumption in children and negative health consequences.
  • Findings underscore the importance of addressing SSB intake to mitigate childhood risk factors for chronic diseases.
  • Results can inform public health policies and interventions aimed at improving child health.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
403
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
15.1K
Sugars as Energy Storage Molecules01:10

Sugars as Energy Storage Molecules

Sugar (a simple carbohydrate) metabolism (chemical reactions) is a classic example of the many cellular processes that use and produce energy. Living things consume sugar as a major energy source because sugar molecules have considerable energy stored within their bonds. Consumed carbohydrates have their origins in photosynthesizing organisms like plants. During photosynthesis, plants use the energy of sunlight to convert carbon dioxide gas into sugar molecules, like glucose. Because this...
7.1K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
950
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
398